Logo
x

Search

Subscribe Now

Diabetic Retinopathy

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021

Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 202...

  • November 15, 2021
Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting

Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting

  • October 11, 2021
AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopath...

  • May 7, 2021
Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

  • September 8, 2020
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy

Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy

  • February 10, 2020
Regeneron's Eylea (aflibercept) Injection Receives FDA's Approval for Diabetic Retinopathy

Regeneron's Eylea (aflibercept) Injection Receives FDA's Approval for Diabetic Retinopathy

  • May 14, 2019
Regeneron Receives Complete Response Letter on the BLA for Aflibercept to Treat Wet Age-Related Macular Degeneration, Diabetic Macular Edema, and Diabetic Retinopathy

    Regeneron Receives Complete Response Letter on the BLA for Aflibercept to Treat Wet Age-Related Macular Degeneration, Diabetic Mac...

    • June 28, 2023
    REGENXBIO Presents Interim P-II (ALTITUDE) Trial Results of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery at 55th Annual Retina Society Meeting

      REGENXBIO Presents Interim P-II (ALTITUDE) Trial Results of RGX-314 for Diabetic Retinopathy Using Suprachoroidal Delivery at 55th...

      • November 3, 2022
      Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 2021

        Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 202...

        • November 15, 2021
        Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting

          Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting

          • October 11, 2021
          AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

            AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopath...

            • May 7, 2021
            Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

              Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

              • September 8, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.